A Study on the Expression and Clinical Significance of AIB1 Protein in Ovarian Borderline Epithelial Tumor

doi:10.3877/cma.j.issn.1673-5250.2008.03.105

Objective

To investigate the expression and clinical significance of AIB1(amplified in breast cancer 1) protein in ovarian borderline epithelial tumor.

Methods

We examined the AIB1 expression levels and its relations to clinicopathological features in 24 normal ovaries, 24 cases of ovarian benign epithelial tumor, 18 cases of ovarian borderline epithelial tumor and 69 cases of epithelial ovarian cancer by immunohistochemical method SP. We also simultaneously examined the expression of estrogen receptor (ER), progesterone receptor(PR), p53 protein and bcl-2 protein in ovarian borderline epithelial tumors.

Results

①The positive expression rate of AIB1 protein in ovarian borderline epithelial tumors was 38.89%, which was significantly lower than that in ovarian cancers (65.22%), higher than that in normal ovaries(8.33%), but the difference between the borderline and benign ovarian tumors was not significant. ②The expression of AIB1 protein in clinical stageⅡ~Ⅲ was higher than that in stageⅠ, but the expression levels in different histological groups were not significant. ③AIB1 protein expression was positively correlated with estrogen receptor, progesterone receptor, p53 protein, but there was no correlation between expressions of AIB1 and bcl-2 protein.

Conclusion

The expression of AIB1 may play a role in the ovarian carcinogenesis of the borderline epithelial tumor through steroid receptor and mutational p53 protein signal transduction pathways.

Key words: ovarian tumor, borderline tumor, AIB1 protein, immunohistochemistry

	1　Kuang SQ, Liao L, Wang S, et al. Mice lacking the amplified in breast cancer 1/steroid receptor coactivator－3 are resistant to chemical carcinogen－induced mammary tumorigenesis. Cancer Res，2005，65(17)：7993－8002.
	2　韩肖燕，郄明蓉，张雪梅等. AIB1蛋白在妇科肿瘤中的表达. 四川大学学报(医学版)，2007，38(2)：246－249.
	3　曹泽毅主编. 中华妇产科学下册．第2版. 北京：人民卫生出版社，2005，1908－1909.
	4　Henke RT, Haddad BR, Kim SE, et al. Overexpression of the nuclear receptor coactivator AIB1 (SRC－3) during progression of pancreatic adenocarcinoma. Clin Cancer Res, 2004, 10(18 Pt 1): 6134－6142.
	5　王建六，张岫屏，魏丽惠. 卵巢上皮性肿瘤雌、孕激素受体亚型的初步研究. 中国肿瘤临床，2002, 29(7)：457－460.
	6　倪灿荣，马大烈，戴益民主编. 免疫组织化学实验技术及应用. 北京：化学工业出版社，2006, 323.
	7　Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science, 1997, 277(5328): 965－968.
	8　Liao L, Kuang SQ, Yuan Y, et al. Molecular structure and biological function of the cancer－amplified nuclear receptor coactivator SRC－3/AIB1. J Steroid Biochem Mol Biol, 2002, 83(1－5)：3－14.
	9　Font de Mora J, Brown M. AIB1 is a conduit for kinase－mediated growth factor signaling to the estrogen receptor. Mol Cell Biol, 2000, 20(14): 5041－5047.
	10　Sarraf S, Tejada R, Abawi M, et al. The human ovarian teratocarcinoma cell line PA－1 demonstrates a single translocation: Analysis with fluorescence in situ hybridization, spectral karyotyping, and bacterial artificial chromosome microarray. Cancer Genet Cytogenet, 2005, 161(1): 63－69.
	11　Tanner MM, Grenman S, Koul A, et al. Frequent amplification of chromosomal region 20q12－q13 in ovarian cancer. Clin Cancer Res, 2000, 6(5): 1833－1839.
	12　郎景和主编. 妇科手术笔记．第2卷. 北京：中国科学技术出版社，2004，36.
	13　Bouras T, Southey MC, Venter DJ. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res, 2001, 61(3)：903－907.
	14　Zhou HJ, Yan J, Luo W, et al. SRC－3 is required for prostate cancer cell proliferation and survival. Cancer Res，2005, 65(17): 7976－7983.

[1]	Ju Lu, Sheng Zhao, Jianhua Fan, Yanduo Gao. Performance of IOTA simple rules, GI-RADS, and O-RADS in differentiating between benign and malignant adnexal lesions[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(05): 484-490.
[2]	Yang Zhao, Yingcong Xiao, Yan Ju, Xiaozhi Dang, Linli Cai, Wenxin Xue, Yang Li, Yao Xiao, Yuqi Guo, Hongping Song. Clinical value of automated breast ultrasound combined with immunohistochemistry in early prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(04): 361-369.
[3]	Zhuangzhuang Wu, Xiaojuan Zhang, Zehong Shi, yao Shi, Shaoling Yuan. Prognostic value of ultrasound combined with mammography and PR and HER-2 status in high-grade and middle-low-grade ductal carcinoma in situ of the breast[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(06): 631-635.
[4]	Yuanyuan He, Jia Li, Hong Yang. Mesonephric adenocarcinoma of uterine cervix: a case report and literature review[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(01): 97-104.
[5]	Xingchen Liu, Juan Liu, Baobao Wei, Jie Liu, Hui Liu. Correlation analysis of abnormal expression of XIAP and XAF1 with ovarian cancer[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 419-427.
[6]	Yifang Chen, Xiaohui Huang. Expression and clinical significance of paraoxonase 2 in hepatocellular carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(03): 186-191.
[7]	Ming Zhang, Ji Wang, Wenxing Zhao. Clinical application of limited pancreatic resection with pancreatic function preservation in benign and borderline tumors[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 562-565.
[8]	Ningning Hu, Yanrong Zhao, Dong Wang, Shengliang Wang, Yuan Guo. The correlation study between the expression of FMNL3 and prognosis in hepatocellular carcinoma liver transplant recipients[J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(05): 283-288.
[9]	Qinliang Si, Shilong Bi, Huixiao Jiao, Shizhao Li, Zheyu Chen, Yudong Wu. Two cases of dedifferentiated liposarcoma of spermatic cord and literature review[J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 585-590.
[10]	Tingxiu Liu, Xinmin Liu, Ying Liu, Juan Sui, Yu Wu, Yujing Zhao, Hong Bi, Xuemei Sun, Xiuhua Fan. Discuss the safety and feasibility of laparoscopic oophorectomy approach after abdominoplasty[J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2024, 17(03): 189-192.
[11]	Ruiyi Tan. Current advances and developments in diagnosis and treatment of small cell osteosarcoma[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(08): 781-784.
[12]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[13]	Wenbo Niu, Fengpeng Wu, Yueping Liu, Chaoxi Zhou, Juan Zhang, Xuhua Hu, Baokun Li, Gueying Wang. Neoadjuvant chemoradiotherapy for treatment of locally advanced rectal cancer: Efficacy and tumor immune microenvironment changes[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 519-523.
[14]	Yunyao Zhang, Jing Wang, Aijuan Fan, Haiping Mou. Meta-analysis of the clinical value of ultrasonography in the diagnosis of borderline ovarian tumors[J]. Chinese Journal of Diagnostics(Electronic Edition), 2024, 12(02): 85-89.
[15]	Gaocai Mao, Jianbo Zhang, Yifang Yuan, Xiaobo Mao, Huiyong Dai, Zhe Wang. Diagnostic characteristics of clear cell type oxyphilic adenoma of salivary gland in retroauricular lymph nodes[J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(04): 261-265.

Viewed

Full text

Abstract

Please choose a citation manager

Content to export